$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2011 Q4 Form 10-K Financial Statement

#000153217613000004 Filed on February 15, 2013

Income Statement

Concept	2011 Q4	2011 Q3	2011 Q2
Revenue	$123.0M	$102.8M	$107.8M
YoY Change	-8.02%	-2.99%	-6.98%
Cost Of Revenue	$3.000M	$450.0K	$400.0K
YoY Change	400.0%	12.5%	0.0%
Gross Profit	$120.0M	$102.4M	$107.4M
YoY Change	-9.84%	-3.05%	-7.01%
Gross Profit Margin	97.58%	99.56%	99.62%
Selling, General & Admin	$36.30M	$32.92M	$24.60M
YoY Change	76.21%	109.66%	67.35%
% of Gross Profit	30.25%	32.15%	22.91%
Research & Development	$129.0M	$127.9M	$143.1M
YoY Change	3.04%	4.86%	14.94%
% of Gross Profit	107.5%	124.95%	133.24%
Depreciation & Amortization	$7.900M	$8.300M	$7.900M
YoY Change	29.51%	69.39%	75.56%
% of Gross Profit	6.58%	8.11%	7.36%
Operating Expenses	$165.4M	$160.8M	$167.7M
YoY Change	13.37%	16.8%	20.47%
Operating Profit	-$45.40M	-$58.46M	-$60.30M
YoY Change	254.69%	82.11%	154.43%
Interest Expense	-$9.500M	$4.061M	-$4.000M
YoY Change	280.0%	-284.59%	73.91%
% of Operating Profit
Other Income/Expense, Net	$800.0K	-$3.346M	$1.000M
YoY Change	33.33%	-769.2%	66.67%
Pretax Income	-$54.10M	-$61.80M	-$63.40M
YoY Change	270.55%	82.31%	148.63%
Income Tax	-$600.0K	$562.0K	-$900.0K
% Of Pretax Income
Net Earnings	-$53.44M	-$62.37M	-$62.51M
YoY Change	266.05%	83.97%	145.12%
Net Earnings / Revenue	-43.46%	-60.65%	-57.98%
Basic Earnings Per Share		-$0.68
Diluted Earnings Per Share	-$581.7K	-$0.68	-$691.4K
COMMON SHARES
Basic Shares Outstanding		91.05M shares
Diluted Shares Outstanding		91.05M shares

Balance Sheet

Concept	2011 Q4	2011 Q3	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$527.0M	$245.0M	$310.0M
YoY Change	111.65%	-48.85%	1.31%
Cash & Equivalents	$483.6M	$206.4M	$254.0M
Short-Term Investments	$43.00M	$39.00M	$55.00M
Other Short-Term Assets	$36.00M	$16.00M	$19.00M
YoY Change	38.46%	14.29%	18.75%
Inventory	$16.61M
Prepaid Expenses
Receivables	$28.25M	$75.00M	$82.00M
Other Receivables	$0.00	$3.000M	$3.000M
Total Short-Term Assets	$665.8M	$340.0M	$413.0M
YoY Change	85.97%	-40.97%	-1.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$368.0M	$364.0M	$362.0M
YoY Change	5.9%	14.47%	23.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$276.0M	$258.0M	$251.0M
YoY Change	-25.41%	578.95%	258.57%
Other Assets	$6.243M	$21.00M	$20.00M
YoY Change	-55.41%	110.0%	100.0%
Total Long-Term Assets	$657.8M	$643.0M	$634.0M
YoY Change	-10.01%	75.68%	69.97%
TOTAL ASSETS
Total Short-Term Assets	$665.8M	$340.0M	$413.0M
Total Long-Term Assets	$657.8M	$643.0M	$634.0M
Total Assets	$1.324B	$983.0M	$1.047B
YoY Change	21.54%	4.35%	32.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.00M	$21.00M	$27.00M
YoY Change	55.56%	-8.7%	68.75%
Accrued Expenses	$68.00M	$58.00M	$55.00M
YoY Change	88.89%	11.54%	27.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$148.3M	$133.0M	$136.0M
YoY Change	36.03%	-0.75%	13.33%
LONG-TERM LIABILITIES
Long-Term Debt	$435.0M	$159.0M	$159.0M
YoY Change	173.58%	0.63%	1.27%
Other Long-Term Liabilities	$6.443M	$262.0M	$274.0M
YoY Change	-97.8%	-13.25%	92.96%
Total Long-Term Liabilities	$6.443M	$421.0M	$433.0M
YoY Change	-98.57%	-8.48%	44.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$148.3M	$133.0M	$136.0M
Total Long-Term Liabilities	$6.443M	$421.0M	$433.0M
Total Liabilities	$837.9M	$555.0M	$569.0M
YoY Change	49.08%	-6.57%	35.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.267B
YoY Change
Common Stock	$91.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$485.7M	$428.3M	$478.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.324B	$983.0M	$1.047B
YoY Change	21.54%	4.35%	32.36%

Cashflow Statement

Concept	2011 Q4	2011 Q3	2011 Q2
OPERATING ACTIVITIES
Net Income	-$53.44M	-$62.37M	-$62.51M
YoY Change	266.05%	83.97%	145.12%
Depreciation, Depletion And Amortization	$7.900M	$8.300M	$7.900M
YoY Change	29.51%	69.39%	75.56%
Cash From Operating Activities	-$50.30M	-$46.80M	-$34.00M
YoY Change	22.98%	-128.98%	198.25%
INVESTING ACTIVITIES
Capital Expenditures	-$11.30M	-$8.900M	-$14.80M
YoY Change	-65.02%	-59.73%	-34.51%
Acquisitions
YoY Change
Other Investing Activities	-$22.60M	$8.000M	$157.8M
YoY Change	-92.99%	-88.93%	509.27%
Cash From Investing Activities	-$33.90M	-$900.0K	$143.0M
YoY Change	-90.44%	-101.79%	4105.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	361.4M	-300.0K	10.10M
YoY Change	97.7%	-118.75%	274.07%
NET CHANGE
Cash From Operating Activities	-50.30M	-46.80M	-34.00M
Cash From Investing Activities	-33.90M	-900.0K	143.0M
Cash From Financing Activities	361.4M	-300.0K	10.10M
Net Change In Cash	277.2M	-48.00M	119.1M
YoY Change	-230.32%	-122.5%	-2347.17%
FREE CASH FLOW
Cash From Operating Activities	-$50.30M	-$46.80M	-$34.00M
Capital Expenditures	-$11.30M	-$8.900M	-$14.80M
Free Cash Flow	-$39.00M	-$37.90M	-$19.20M
YoY Change	353.49%	-120.64%	-271.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	111345000	USD
CY2011Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	95625000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	38934000	USD
CY2011Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	27736000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28254000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	593207000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	180513000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	158139000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1166000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1862000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1763508000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1754824000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120623000	USD
CY2011Q4	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120600000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94181000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39897000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56609000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	93800000	USD
CY2012	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-824884000	USD
CY2010	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	203690000	USD
CY2011	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	80078000	USD
CY2011Q4	us-gaap	Assets Assets	1323583000	USD
CY2012Q4	us-gaap	Assets Assets	2080490000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	1206012000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	665777000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	354990000	USD
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	325889000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	66835000	USD
CY2011Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	111890000	USD
CY2011Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	111774000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	63442000	USD
CY2011Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	116000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	3393000	USD
CY2011Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	322140000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	351565000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	354958000	USD
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	325159000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	702000	USD
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	1260000	USD
CY2011	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-400000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	651000	USD
CY2011Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	152000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	702000	USD
CY2011Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	1260000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	51000	USD
CY2011Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	1108000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	670000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	530000	USD
CY2010	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	2900000	USD
CY2011	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	700000	USD
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	2500000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1300000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230276000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	483610000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	207075000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112572000	USD
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-94503000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	371038000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-253334000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	750965000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-221131000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108003000	USD
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, marketable securities (see Note 6), and accounts receivable. Accounts receivable from product sales of EYLEA and ARCALYST are due from three distributors and several specialty pharmacies, who are the Company's customers. The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. In addition, the Company may insure a portion of its accounts receivables within its overall risk management practices. During 2012, 2011, and 2010, the Company did not recognize any charges for write-offs of accounts receivable related to its marketed products. </font></div></div>
CY2012	us-gaap	Contracts Revenue ContractsRevenue	2900000	USD
CY2010	us-gaap	Contracts Revenue ContractsRevenue	6945000	USD
CY2011	us-gaap	Contracts Revenue ContractsRevenue	6599000	USD
CY2011Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	275019000	USD
CY2012Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	296518000	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	84455000	USD
CY2011	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4216000	USD
CY2010	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2093000	USD
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	556546000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	920764000	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	650983000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4308000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4308000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-300319000	USD
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-340156000	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7995000	USD
CY2011Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1428000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	51640000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	50831000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	248610000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	208342000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-39837000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	120490000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	99659000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	350637000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	579970000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	578542000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	342642000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	148134000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent		USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent		USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	192022000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	340156000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77119000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	282480000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15956000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	23511000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1380000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	14847000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	67734000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	71164000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	53367000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	47092000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2486000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	578542000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	6824000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	1171000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	1428000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4100000	USD
CY2010	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6300000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31082000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36940000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19687000	USD
CY2012Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	99913000	USD
CY2011Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	74781000	USD
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.92
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.45
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.26
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.92
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.02
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.26
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.75
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.45
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.72
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.70
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.08
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.811
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.390
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.054
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.028
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.093
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	42835000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19987000	USD
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	4308000	USD
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities		USD
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities		USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2800000	USD
CY2012Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	65000000	USD
CY2010	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-222892000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	414421000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-104468000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-335848000	USD
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1132000	USD
CY2012	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	-335848000	USD
CY2012Q4	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	-335800000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	340200000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7605000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50016000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10979000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17518000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21118000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	590085000	USD
CY2012	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	340200000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	158151000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-41077000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-40329000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8212000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	52616000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6992000	USD
CY2010	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	5941000	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	277000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	552000	USD
CY2010	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2012	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	990000	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2010	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2011	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	4761000	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	14231000	shares
CY2010	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2010	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	3700000	USD
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	USD
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	USD
CY2010	us-gaap	Interest Expense InterestExpense	9118000	USD
CY2011	us-gaap	Interest Expense InterestExpense	21282000	USD
CY2012	us-gaap	Interest Expense InterestExpense	45304000	USD
CY2011	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		USD
CY2010	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		USD
CY2012	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	29126000	USD
CY2011	us-gaap	Interest Paid Net InterestPaidNet	14725000	USD
CY2012	us-gaap	Interest Paid Net InterestPaidNet	21946000	USD
CY2010	us-gaap	Interest Paid Net InterestPaidNet	12737000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2570000	USD
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1142000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	16614000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	28638000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4862000	USD
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4666000	USD
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3600000	USD
CY2011Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14656000	USD
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8846000	USD
CY2010	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2011	us-gaap	Inventory Write Down InventoryWriteDown	500000	USD
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	17000000	USD
CY2011	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3549000	USD
CY2010	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2122000	USD
CY2012	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2012000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	835105000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	837851000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1323583000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2080490000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163550000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	148271000	USD
CY2010	us-gaap	Licenses Revenue LicensesRevenue	40150000	USD
CY2012	us-gaap	Licenses Revenue LicensesRevenue	23571000	USD
CY2011	us-gaap	Licenses Revenue LicensesRevenue	24858000	USD
CY2011Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	43332000	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	77819000	USD
CY2011Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	275887000	USD
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	271230000	USD
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regeneron Pharmaceuticals, Inc. and its subsidiaries (collectively, the “Company” or “Regeneron”) is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company currently has three marketed products as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States for the treatment of neovascular age-related macular degeneration ("wet AMD") and macular edema following central retinal vein occlusion ("CRVO"), and in the United Kingdom, Germany, Switzerland, Australia, Japan, and certain other countries, for the treatment of wet AMD. The Company commenced sales of EYLEA for the treatment of wet AMD in November 2011 and for the treatment of macular edema following CRVO in September 2012, following receipt of regulatory approvals in the United States. Bayer HealthCare LLC commenced sales of EYLEA for the treatment of wet AMD in the fourth quarter of 2012 following receipt of regulatory approvals in the European Union ("EU") and other regions. Regeneron is collaborating with Bayer HealthCare on the global development and commercialization of EYLEA outside the United States. Regeneron maintains exclusive rights to EYLEA in the United States and is entitled to all profits from any such sales. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZALTRAP</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (ziv-aflibercept) Injection for Intravenous Infusion, known in the scientific literature as VEGF Trap, which is available in the United States for treatment, in combination with 5-fluorouracil, leucovorin, irinotecan ("FOLFIRI"), for patients with metastatic colorectal cancer ("mCRC") that is resistant to or has progressed following an oxaliplatin-containing regimen. Marketing approval for ZALTRAP was received from the U.S. Food and Drug Administration ("FDA") in August 2012. Regeneron and Sanofi globally collaborate on the development and commercialization of ZALTRAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (rilonacept) Injection for Subcutaneous Use, which is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes ("CAPS"), including Familial Cold Auto-inflammatory Syndrome ("FCAS") and Muckle-Wells Syndrome ("MWS"), in adults and children 12 and older. Marketing approval for ARCALYST for the treatment of CAPS was received from the FDA in 2008.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's facilities are primarily located in New York. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting pharmaceutical research, obtaining regulatory approvals, commercializing products, and obtaining and enforcing patents.</font></div></div>
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	243306000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-97646000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	384249000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81073000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	128471000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-437031000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-141682000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74615000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	99222000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-221760000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	750269000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-104468000	USD
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-43447000	USD
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-53443000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	11651000	USD
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-62365000	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	470407000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	76743000	USD
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-62505000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	191468000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-104468000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-221760000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	779395000	USD
CY2010	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3798000	USD
CY2012	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	163300000	USD
CY2010	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	605124000	USD
CY2010	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6996000	USD
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17733000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43292000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-205159000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	457713000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-97472000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	92245000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	8752000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7517000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	7857000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	7772000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7827000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	52520000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	8029000	USD
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7636000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7790000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19569000	USD
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11257000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23100000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6243000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	629000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	696000	USD
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3535000	USD
CY2011Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	1960000	USD
CY2012Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	6550000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6443000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7259000	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6224000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-34049000	USD
CY2010	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4037000	USD
CY2012	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities		USD
CY2010	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities		USD
CY2011	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	117500000	USD
CY2011	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25078000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	470393000	USD
CY2011	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	240391000	USD
CY2011	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	57217000	USD
CY2010	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	99689000	USD
CY2012	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	49337000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	35800000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	56663000	USD
CY2012	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. </font></div></div>
CY2012	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2010	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2011	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	391107000	USD
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200588000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63549000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43587000	USD
CY2011	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	93800000	USD
CY2010	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		USD
CY2012	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		USD
CY2011Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	93800000	USD
CY2011	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations		USD
CY2012	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations		USD
CY2010	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	47544000	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	439209000	USD
CY2010	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	273723000	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	426356000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	526094000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	560453000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	379940000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	367955000	USD
CY2011Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	200000	USD
CY2010Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	200000	USD
CY2012Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	3800000	USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2203000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1667000	USD
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1028000	USD
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	489252000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	529506000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	625554000	USD
CY2012Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	8186000	USD
CY2011Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	7721000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-517054000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1267323000	USD
CY2012	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	423814000	USD
CY2010	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	311332000	USD
CY2011	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	326609000	USD
CY2012	us-gaap	Revenue Recognition Interest RevenueRecognitionInterest	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment Income</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income, which is included in investment income, is recognized as earned.</font></div></div>
CY2012	us-gaap	Revenue Recognition Long Term Contracts RevenueRecognitionLongTermContracts	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company earns collaboration revenue in connection with collaboration agreements to develop and commercialize product candidates and utilize the Company's technology platforms. The terms of these agreements typically include non-refundable up-front licensing payments, research progress (milestone) payments, payments for development activities, and sharing of profits or losses arising from the commercialization of products. Non-refundable up-front license payments, where continuing involvement is required of the Company, are deferred and recognized over the related performance period. The Company estimates its performance period based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Although the Company did not enter into, or materially modify, any collaboration arrangements with multiple-deliverables during the years ended December 31, 2011 and 2012, any future arrangements with multiple deliverables will be divided into separate units of accounting if the deliverables in the arrangement meet certain criteria, including whether the delivered item or items has value to the collaborator on a standalone basis.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Payments which are based on achieving a specific substantive performance milestone, involving a degree of risk, are recognized as revenue when the milestone is achieved and the related payment is due and non-refundable, provided there is no future service obligation associated with that milestone. Substantive performance milestones typically consist of significant achievements in the development life-cycle of the related product candidate, such as completion of clinical trials, filing for approval with regulatory agencies, and receipt of approvals by regulatory agencies. In determining whether a payment is deemed to be a substantive performance milestone, the Company takes into consideration (i) the enhancement in value to the related development product candidate, (ii) the Company's performance and relative level of effort required to achieve the milestone, (iii) whether the milestone relates solely to past performance, and (iv) whether the milestone payment is considered reasonable relative to all of the deliverables and payment terms. Payments for achieving milestones which are not considered substantive are deferred and recognized over the related performance period. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration agreements that include varying arrangements regarding which parties perform and bear the costs of research and development activities. The Company may</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">share the costs of research and development activities with a collaborator, such as in the Company's EYLEA collaboration with Bayer HealthCare, or the Company may be reimbursed for all or a significant portion of the costs of the Company's research and development activities, such as in the Company's ZALTRAP and antibody collaborations with Sanofi. The Company records its internal and third-party development costs associated with these collaborations as research and development expenses. When the Company is entitled to reimbursement of all or a portion of the research and development expenses that it incurs under a collaboration, the Company records those reimbursable amounts as collaboration revenue proportionately as the Company recognizes its expenses. If the collaboration is a cost-sharing arrangement in which both the Company and its collaborator perform development work and share costs, in periods when the Company's collaborator incurs development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of the collaborator's development expenses that the Company is obligated to reimburse. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may also be obligated to use commercially reasonable efforts to supply commercial product to its collaborators. In such cases, the Company is reimbursed for its manufacturing costs as commercial product is shipped to its collaborators; however, recognition of such cost reimbursements as collaboration revenue is deferred until the product is sold by the Company's collaborators to third-party customers, at which time the Company's risk of inventory loss no longer exists. In addition, at that time, the related manufacturing costs for the sold product, which had been capitalized into inventory, are recognized by the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company's collaboration agreements, product sales and cost of sales are recorded by the Company's collaborators. The Company shares in any profits or losses arising from the commercialization of collaboration products. The Company records its share of the profits or losses, representing net product sales less cost of goods sold and shared commercialization and other expenses, from commercialization of such products as collaboration revenue. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with non-refundable licensing payments, the Company's performance period estimates are principally based on projections of the scope, progress, and results of its research and development activities. Due to the variability in the scope of activities and length of time necessary to develop a drug product, changes to development plans as programs progress, and uncertainty in the ultimate requirements to obtain governmental approval for commercialization, revisions to performance period estimates are likely to occur periodically, and could result in material changes to the amount of revenue recognized each year in the future. In addition, estimated performance periods may change if development programs encounter delays, or the Company and its collaborators decide to expand or contract the clinical plans for a drug candidate in various disease indications. Also, if a collaborator terminates an agreement in accordance with the terms of the agreement, the Company would recognize as revenue any unamortized remainder of an up-front or previously deferred payment at the time of the termination. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2012Q4	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	10000000	USD
CY2012	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales consist of U.S. sales of EYLEA and ARCALYST. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated. The Company's written contracts with its customers stipulate product is shipped freight on board destination (FOB destination). The Company records revenue from product sales upon delivery to its customers. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in the United States to three distributors and several specialty pharmacies. The Company sells ARCALYST in the United States to two specialty pharmacies. Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product. For EYLEA, the distributors and specialty pharmacies generally sell the product directly to healthcare providers, whereas for ARCALYST, the specialty pharmacies sell the product directly to patients. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Rebates and Chargebacks: </font><font style="font-family:inherit;font-size:10pt;">The Company estimates reductions to product sales for Medicaid and Veterans' Administration ("VA") programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and, in the case of EYLEA, estimated payer mix based on third-party market research data, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing offered to VA, Public Health Services ("PHS"), and other institutions (collectively, “qualified healthcare providers”) represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution-Related Fees: </font><font style="font-family:inherit;font-size:10pt;">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Pay Discounts: </font><font style="font-family:inherit;font-size:10pt;"> No prompt pay discounts are currently offered to the Company's customers on sales of EYLEA. In connection with sales of ARCALYST, the Company offers discounts to its customers for prompt payments. The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount. Therefore, the Company accrues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the prompt pay discount that is based on the gross amount of each ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">invoice, at the time of sale.</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns: </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA to healthcare providers and ARCALYST to patients using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2012	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">Technology Licensing</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company's </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune</font><font style="font-family:inherit;font-size:10pt;"> technology in its internal research programs. The terms of these agreements include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company's </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune </font><font style="font-family:inherit;font-size:10pt;">technology. Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods.</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2011	us-gaap	Revenues Revenues	445824000	USD
CY2012	us-gaap	Revenues Revenues	1378477000	USD
CY2010	us-gaap	Revenues Revenues	459074000	USD
CY2011Q2	us-gaap	Revenues Revenues	107810000	USD
CY2012Q4	us-gaap	Revenues Revenues	414602000	USD
CY2011Q1	us-gaap	Revenues Revenues	112204000	USD
CY2012Q3	us-gaap	Revenues Revenues	427687000	USD
CY2011Q3	us-gaap	Revenues Revenues	102833000	USD
CY2011Q4	us-gaap	Revenues Revenues	122977000	USD
CY2012Q1	us-gaap	Revenues Revenues	231789000	USD
CY2012Q2	us-gaap	Revenues Revenues	304399000	USD
CY2011	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	44686000	USD
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	858093000	USD
CY2010	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	25254000	USD
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	117261000	USD
CY2010	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	65201000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	210755000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	94157000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	56094000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	39897000	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	38877	shares
CY2011Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	91761	shares
CY2012Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	63937	shares
CY2010Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6325000	shares
CY2010	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	2867000	USD
CY2012	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6325000	USD
CY2011	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6979000	USD
CY2010	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	174828000	USD
CY2010Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	174800000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25262000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43615000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	67174000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1245385000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	485732000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	527815000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	396762000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5596000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11274000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12819000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	9415000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities		USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2192000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3550000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1873000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	9269000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3805000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8400000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4200000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	12000000	USD
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates which could have a significant impact on the Company's financial statements include:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product rebates, chargebacks, distribution-related fees, and returns in connection with the recognition of product sales revenue. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements to develop and commercialize product candidates and utilize the Company's technology platforms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periods over which certain clinical trial costs, including costs for clinical activities performed by contract research organizations, are recognized as research and development expenses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the recognition of expense, using a blended royalty rate, related to the Company's non-exclusive license with Genentech, Inc., the Company's estimate of cumulative EYLEA sales through May 7, 2016 (see Note 13b).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with stock option awards, (i) the fair value of stock options on their date of grant using the Black-Scholes option-pricing model, based on assumptions with respect to (a) expected volatility of the Company's Common Stock price, (b) the periods of time for which employees and members of the Company's board of directors are expected to hold their options prior to exercise (expected lives), (c) expected dividend yield on the Company's Common Stock, and (d) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options' expected lives; (ii) the number of stock option awards that are expected to be forfeited; and (iii) with respect to performance-based stock option awards, if and when the options' performance conditions are considered to be probable of attainment. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's determination of whether marketable securities are other-than-temporarily impaired. The Company conducts a review of its portfolio of marketable securities, using both quantitative and qualitative factors, to determine, for securities whose current fair value is less than their cost, whether the decline in fair value below cost is other-than-temporary. In making this determination, the Company considers factors such as the length of time and the extent to which fair value has been less than cost, financial condition and near-term prospects of the issuer, recommendations of investment advisors, and forecasts of economic, market, or industry trends. This review process also includes an evaluation of the Company's ability and intent to hold individual securities until they mature or their full value can be recovered. This review is subjective and requires a high degree of judgment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Useful lives of property, plant, and equipment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, which is written-down, as appropriate. In addition, capitalization of inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The extent to which deferred tax assets and liabilities are offset by a valuation allowance. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the Company's collaborations with Sanofi and Bayer HealthCare:</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Sanofi collaboration revenue is the Company's share of profits or losses from commercialization of ZALTRAP, </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">which is provided by Sanofi, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Bayer HealthCare collaboration revenue is the Company's share of profits or losses from commercialization of EYLEA outside the United States, which is provided by Bayer HealthCare, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in research and development expenses is the Company's share of EYLEA development expenses incurred by Bayer HealthCare, including the Company's share of Bayer HealthCare estimated development expenses for the most recent fiscal quarter.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These estimates for the most recent fiscal quarter are adjusted, if necessary, in the subsequent quarter to reflect actual amounts for the quarter. </font></div></div>
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2218000	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	18826000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	62251000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	45643000	USD
CY2010	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20697000	shares
CY2011	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115382000	shares
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82926000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90610000	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82926000	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94685000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90610000	shares
CY2011Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	6200000	USD
CY2010Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	10700000	USD
CY2012Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	8600000	USD
CY2012Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	10985000	USD
CY2011Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	9850000	USD
CY2011Q4	regn	Accrued Sales Related Deductions And Royalties AccruedSalesRelatedDeductionsAndRoyalties	3947000	USD
CY2012Q4	regn	Accrued Sales Related Deductions And Royalties AccruedSalesRelatedDeductionsAndRoyalties	21870000	USD
CY2011	regn	Adjustment To Additional Paid In Capital Cost Of Convertible Note Hedge AdjustmentToAdditionalPaidInCapitalCostOfConvertibleNoteHedge	117500000	USD
CY2011	regn	Adjustments Related To Tax Withholding For Share Based Compensation Restricted Stock AdjustmentsRelatedToTaxWithholdingForShareBasedCompensationRestrictedStock	2638000	USD
CY2012	regn	Adjustments Related To Tax Withholding For Share Based Compensation Restricted Stock AdjustmentsRelatedToTaxWithholdingForShareBasedCompensationRestrictedStock	50466000	USD
CY2011	regn	Adjustments Related To Tax Withholding For Share Based Compensation Stock Options AdjustmentsRelatedToTaxWithholdingForShareBasedCompensationStockOptions	22440000	USD
CY2012	regn	Adjustments Related To Tax Withholding For Share Based Compensation Stock Options AdjustmentsRelatedToTaxWithholdingForShareBasedCompensationStockOptions	112834000	USD
CY2010	regn	Adjustments Related To Tax Withholding For Share Based Compensation Stock Options AdjustmentsRelatedToTaxWithholdingForShareBasedCompensationStockOptions	3798000	USD
CY2010	regn	Advance Payment Received Due To Amended Licensing Agreement AdvancePaymentReceivedDueToAmendedLicensingAgreement	165000000	USD
CY2011Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	31629000	USD
CY2012Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	33809000	USD
CY2011Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	162593000	USD
CY2012Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	131822000	USD
CY2011Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	20011000	USD
CY2012Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	17022000	USD
CY2012Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	76520000	USD
CY2011Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	86017000	USD
CY2012Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	24437000	USD
CY2011Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	31371000	USD
CY2011Q4	regn	Facility Lease Obligations Current FacilityLeaseObligationsCurrent	1006000	USD
CY2012Q4	regn	Facility Lease Obligations Current FacilityLeaseObligationsCurrent	1374000	USD
CY2011Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	159508000	USD
CY2012Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	159436000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due FacilityLeasesFutureMinimumPaymentsDue	225052000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due Current FacilityLeasesFutureMinimumPaymentsDueCurrent	17462000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due Due In Five Years FacilityLeasesFutureMinimumPaymentsDueDueInFiveYears	19004000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due Due In Four Years FacilityLeasesFutureMinimumPaymentsDueDueInFourYears	18604000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due Due In Three Years FacilityLeasesFutureMinimumPaymentsDueDueInThreeYears	18214000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due Due In Two Years FacilityLeasesFutureMinimumPaymentsDueDueInTwoYears	17833000	USD
CY2012Q4	regn	Facility Leases Future Minimum Payments Due Due Thereafter FacilityLeasesFutureMinimumPaymentsDueDueThereafter	133935000	USD
CY2011	regn	Income Tax Expense Benefit Resulting From Provision In American Recovery And Reinvestment Act Of2009 IncomeTaxExpenseBenefitResultingFromProvisionInAmericanRecoveryAndReinvestmentActOf2009	-700000	USD
CY2012	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	715000	shares
CY2011	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares		shares
CY2010	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares		shares
CY2012	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	16000000	USD
CY2011	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	15600000	USD
CY2012Q4	regn	Marketable Debt Securities Collateral MarketableDebtSecuritiesCollateral	3200000	USD
CY2011Q4	regn	Marketable Debt Securities Collateral MarketableDebtSecuritiesCollateral	3300000	USD
CY2010	regn	Non Cash Interest Expense NonCashInterestExpense	43000	USD
CY2011	regn	Non Cash Interest Expense NonCashInterestExpense	5101000	USD
CY2012	regn	Non Cash Interest Expense NonCashInterestExpense	22925000	USD
CY2011	regn	Other Collaboration Revenue OtherCollaborationRevenue	43072000	USD
CY2012	regn	Other Collaboration Revenue OtherCollaborationRevenue	70099000	USD
CY2010	regn	Other Collaboration Revenue OtherCollaborationRevenue	75393000	USD
CY2012Q4	regn	Percentage Of Prompt Pay Discount Company Accrues PercentageOfPromptPayDiscountCompanyAccrues	1
CY2012	regn	Percentage Of Start Up Costs Of Total Contract Value Maximum PercentageOfStartUpCostsOfTotalContractValueMaximum	0.20
CY2012	regn	Percentage Of Start Up Costs Of Total Contract Value Minimum PercentageOfStartUpCostsOfTotalContractValueMinimum	0.10
CY2012	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2010	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	10300000	USD
CY2011	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	9300000	USD
CY2012	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	10900000	USD
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2012Q2	dei	Entity Public Float EntityPublicFloat	10364000000	USD
CY2012	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes

Files In Submission

Name	View Source	Status
0001532176-13-000004-index-headers.html	Edgar Link	pending
0001532176-13-000004-index.html	Edgar Link	pending
0001532176-13-000004.txt	Edgar Link	pending
0001532176-13-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-123112x10k.htm	Edgar Link	pending
regn-20121231.xml	Edgar Link	completed
regn-20121231.xsd	Edgar Link	pending
regn-20121231_cal.xml	Edgar Link	unprocessable
regn-20121231_def.xml	Edgar Link	unprocessable
regn-20121231_lab.xml	Edgar Link	unprocessable
regn-20121231_pre.xml	Edgar Link	unprocessable
regn-ex_211x12312012x10k.htm	Edgar Link	pending
regn-ex_231x12312012x10k.htm	Edgar Link	pending
regn-ex_311x12312012x10k.htm	Edgar Link	pending
regn-ex_312x12312012x10k.htm	Edgar Link	pending
regn-ex_32x12312012x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stockpricechart201210k.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2011 Q4 Form 10-K Financial Statement

#000153217613000004 Filed on February 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2011 Q4 Form 10-K Financial Statement

#000153217613000004 Filed on February 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn